Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Xuemei Xie, Jangsoon Lee, Toshiaki Iwase, Megumi Kai & Naoto T Ueno. (2022) Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape. Expert Opinion on Therapeutic Targets 26:5, pages 405-425.
Read now
Read now
Alexis Q. Dean, Shen Luo, Julianne D. Twomey & Baolin Zhang. (2021) Targeting cancer with antibody-drug conjugates: Promises and challenges. mAbs 13:1.
Read now
Read now
Muhammad Kalim, Jie Chen, Shenghao Wang, Caiyao Lin, Saif Ullah, Keying Liang, Qian Ding, Shuqing Chen & Jinbiao Zhan. (2017) Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates. Drug Design, Development and Therapy 11, pages 2265-2276.
Read now
Read now
Jesus Anampa & Joseph A. Sparano. (2017) New agents for the management of resistant metastatic breast cancer. Expert Opinion on Pharmacotherapy 18:17, pages 1815-1831.
Read now
Read now
Gordana Maric, April AN Rose, Matthew G Annis & Peter M Siegel. (2013) Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. OncoTargets and Therapy 6, pages 839-852.
Read now
Read now
David M Goldenberg & Robert M Sharkey. (2012) Using antibodies to target cancer therapeutics. Expert Opinion on Biological Therapy 12:9, pages 1173-1190.
Read now
Read now
Articles from other publishers (19)
Claudia Ceci, Pedro Miguel Lacal & Grazia Graziani. (2022) Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential. Pharmacology & Therapeutics 236, pages 108106.
Crossref
Crossref
J. Edward FisherJr.Jr.. (2021) Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates. Antibodies 10:2, pages 15.
Crossref
Crossref
Qi-Ting Zhang, Ze-Dong Liu, Ze Wang, Tao Wang, Nan Wang, Ning Wang, Bin Zhang & Yu-Fen Zhao. (2021) Recent Advances in Small Peptides of Marine Origin in Cancer Therapy. Marine Drugs 19:2, pages 115.
Crossref
Crossref
Hongnan Mo & Binghe Xu. (2020) Progress in systemic therapy for triple-negative breast cancer. Frontiers of Medicine 15:1, pages 1-10.
Crossref
Crossref
Atefeh Razazan & Javad Behravan. (2019) Single peptides and combination modalities for triple negative breast cancer. Journal of Cellular Physiology 235:5, pages 4089-4108.
Crossref
Crossref
Hamdy A. Azim, Marwan Ghosn, Karima Oualla & Loay Kassem. (2019) Personalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020. The Breast Journal 26:1, pages 69-80.
Crossref
Crossref
Manisha Nigam, Hafiz Ansar Rasul Suleria, Mohammad Hosein Farzaei & Abhay Prakash Mishra. (2019) Marine anticancer drugs and their relevant targets: a treasure from the ocean. DARU Journal of Pharmaceutical Sciences 27:1, pages 491-515.
Crossref
Crossref
Masato Kobayashi, Jin-Sung Chung, Muhammad Beg, Yull Arriaga, Udit Verma, Kevin Courtney, John Mansour, Barbara Haley, Saad Khan, Yutaka Horiuchi, Vijay Ramani, David Harker, Purva Gopal, Farshid Araghizadeh, Ponciano D. CruzJrJr & Kiyoshi Ariizumi. (2019)
Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the
In Vitro
Integrity of T Cells from Cancer Patients
. Clinical Cancer Research 25:2, pages 828-838.
Crossref
Crossref
Saskia H. Hanemaaijer, Stephanie E. van Gijn, Sjoukje F. Oosting, Boudewijn E.C. Plaat, Kirsten L. Moek, Ed M. Schuuring, Bernard F.A.M. van der Laan, Jan L.N. Roodenburg, Marcel A.T.M. van Vugt, Bert van der Vegt & Rudolf S.N. Fehrmann. (2018) Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma. Oral Oncology 80, pages 33-39.
Crossref
Crossref
Daniel Merk & Manfred Schubert-Zsilavecz. 2017. Drug Selectivity. Drug Selectivity
207
245
.
Kedan Lin, Bonnee Rubinfeld, Crystal Zhang, Ron Firestein, Eric Harstad, Leslie Roth, Siao Ping Tsai, Melissa Schutten, Keyang Xu, Maria Hristopoulos & Paul Polakis. (2015)
Preclinical Development of an Anti-NaPi2b (
SLC34A2
) Antibody–Drug Conjugate as a Therapeutic for Non–Small Cell Lung and Ovarian Cancers
. Clinical Cancer Research 21:22, pages 5139-5150.
Crossref
Crossref
G Maric, M G Annis, Z Dong, A A N Rose, S Ng, D Perkins, P A MacDonald, V Ouellet, C Russo & P M Siegel. (2015) GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis. Oncogene 34:43, pages 5494-5504.
Crossref
Crossref
Johanna BendellMansoor SalehApril A.N. RosePeter M. SiegelLowell HartSurendra SirpalSuzanne JonesJennifer GreenElizabeth CrowleyRonit SimantovTibor KelerThomas DavisLinda Vahdat. (2014) Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology 32:32, pages 3619-3625.
Crossref
Crossref
Chiara Fiorentini, Serena Bodei, Francesca Bedussi, Martina Fragni, Sara Anna Bonini, Claudio Simeone, Danilo Zani, Alfredo Berruti, Cristina Missale, Maurizio Memo, PierFranco Spano & Sandra Sigala. (2014) GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. Experimental Cell Research 323:1, pages 100-111.
Crossref
Crossref
Nai-Kong V. Cheung. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
508
518.e7
.
Angelo G?mez-Pozo, Nuria Ibarz Ferrer, Eva Ciruelos, Roc?o L?pez-Vacas, Fernando Garc?a Mart?nez, Enrique Espinosa & Juan ?ngel Fresno Vara. (2013) Shotgun proteomics of archival triple-negative breast cancer samples. PROTEOMICS - Clinical Applications 7:3-4, pages 283-291.
Crossref
Crossref
Birte Nolting. 2013. Antibody-Drug Conjugates. Antibody-Drug Conjugates
71
100
.
Ingrid Sassoon & Véronique Blanc. 2013. Antibody-Drug Conjugates. Antibody-Drug Conjugates
1
27
.
Peter D Senter & Eric L Sievers. (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nature Biotechnology 30:7, pages 631-637.
Crossref
Crossref